Metropolis Healthcare reported strong financial results for Q2 and H1 FY26. Q2FY26 revenue reached INR 429 Cr, up 23% YoY, with EBITDA at INR 109 Cr. Organic growth remained robust, driven by preventive health check-ups and specialty segments. The board approved a dividend of ₹4 per share. The company continues to expand its network and focus on digital transformation and sustainability.
Financial Performance Highlights
Metropolis Healthcare showcased impressive financial growth in its latest earnings report:
- Q2FY26 Revenue: Increased to INR 429 Cr, a growth of 23% YoY
- Q2FY26 EBITDA: Stood at INR 109 Cr with margins at 25.4%
- Q2FY26 PAT: Reached INR 53 Cr, reflecting a 13% YoY increase
For the first half of the fiscal year:
- H1FY26 Revenue: Recorded at INR 815 Cr, up 23% YoY
- H1FY26 EBITDA: Reached INR 198 Cr
- H1FY26 PAT: Stood at INR 98 Cr
Organic Growth & Key Segments
The company’s organic business demonstrated double-digit growth, supported by key segments:
- Preventive health check-ups like TruHealth and specialty segments drove growth.
- Q2FY26 EBITDA margin for the organic business was 26.8%.
B2C & B2B Performance
- B2C Revenue: Increased by 11% YoY, driven by high-value scientific upselling.
- B2B Revenue: Grew by 14% YoY, supported by hospital-led high-value outsourcing and clinical trial business.
Network Expansion
- The company expanded its network to approximately 750 towns.
- Addition of 96 Labs
- Service network increased by +2,195 Centres.
Strategic Initiatives
- Metropolis is focusing on its 3.0 strategy, emphasizing strengthening the core business, expanding into adjacencies, and driving new market expansion.
- The company remains committed to digital transformation and sustainability initiatives.
Source: BSE